| scholarly article | Q13442814 |
| P356 | DOI | 10.1126/SCIENCE.318.5853.1048 |
| P698 | PubMed publication ID | 18006711 |
| P50 | author | Jon Cohen | Q64697727 |
| P433 | issue | 5853 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| P1104 | number of pages | 2 | |
| P304 | page(s) | 1048-1049 | |
| P577 | publication date | 2007-11-01 | |
| P1433 | published in | Science | Q192864 |
| P1476 | title | AIDS research. Did Merck's failed HIV vaccine cause harm? | |
| P478 | volume | 318 |
| Q36787928 | A DNA vaccine prime followed by a liposome-encapsulated protein boost confers enhanced mucosal immune responses and protection |
| Q36024470 | A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge |
| Q43135807 | AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection |
| Q37859842 | Advances and future challenges in adenoviral vector pharmacology and targeting |
| Q33342850 | Allogeneic lymphocytes persist and traffic in feral MHC-matched mauritian cynomolgus macaques |
| Q28482252 | Altering an artificial Gagpolnef polyprotein and mode of ENV co-administration affects the immunogenicity of a clade C HIV DNA vaccine |
| Q64374980 | An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization |
| Q36692389 | Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara |
| Q35660783 | CD8 T cell cross-reactivity networks mediate heterologous immunity in human EBV and murine vaccinia virus infections |
| Q33315029 | Can the new humanized mouse model give HIV research a boost |
| Q36276187 | Circumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques |
| Q39992443 | Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens |
| Q37107609 | Comparison of multiple vaccine vectors in a single heterologous prime-boost trial |
| Q36804198 | Constitutive Activation of the PrfA regulon enhances the potency of vaccines based on live-attenuated and killed but metabolically active Listeria monocytogenes strains |
| Q27657585 | Crystal structure of a 3B3 variantâ A broadly neutralizing HIV-1 scFv antibody |
| Q35235253 | Differences in immunoregulatory cytokine expression patterns in the systemic and genital tract compartments of HIV-1-infected commercial sex workers in Benin |
| Q24629338 | Ebola haemorrhagic fever |
| Q39735960 | Expected epidemiological impact of the introduction of a partially effective HIV vaccine among men who have sex with men in Australia |
| Q36934021 | Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial |
| Q36926697 | HIV-1 Nef: at the crossroads |
| Q64375035 | Heterologous HIV-based lentiviral/adenoviral vectors immunizations result in enhanced HIV-specific immunity |
| Q30378981 | In "Step" with HIV Vaccines? A Content Analysis of Local Recruitment Campaigns for an International HIV Vaccine Study |
| Q35731441 | In vitro sensitization of T cells with DC-associated/delivered HIV constructs can induce a polyfunctional CTL response, memory T-cell response, and virus suppression |
| Q27657228 | Mechanism by which the lectin actinohivin blocks HIV infection of target cells |
| Q34920166 | Mice with human immune system components as in vivo models for infections with human pathogens |
| Q36748019 | Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration |
| Q37236847 | Multiple-infection and recombination in HIV-1 within a longitudinal cohort of women |
| Q35909944 | Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease Control |
| Q48000768 | Nanotechnology in vaccine development: a step forward |
| Q79688333 | New biomedical strategies for HIV-1 prevention in women |
| Q39628648 | Optimization of DNA delivery by three classes of hybrid nanoparticle/DNA complexes |
| Q84992282 | Paradigm change in immune correlation: cellular or humoral? |
| Q45394220 | Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes |
| Q52316326 | Photochemical Internalization of Peptide Antigens Provides a Novel Strategy to Realize Therapeutic Cancer Vaccination. |
| Q37376820 | Potential population health outcomes and expenditures of HIV vaccination strategies in the United States |
| Q36088118 | Prospects for immunisation against Marburg and Ebola viruses |
| Q33614461 | Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites |
| Q37119451 | Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination |
| Q34606818 | Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus |
| Q37058898 | Technical transformation of biodefense vaccines |
| Q37038453 | The challenge of HIV-1 subtype diversity |
| Q24652185 | The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? |
| Q33332191 | The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. |
| Q22241890 | The spread, treatment, and prevention of HIV-1: evolution of a global pandemic |
| Q41218508 | Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck |
| Q36539997 | Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery |
| Q37330748 | Vaccine-induced enhancement of viral infections. |
| Q21131585 | Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates |
| Q37412508 | Viral load and clinical disease enhancement associated with a lentivirus cytotoxic T lymphocyte vaccine regimen |
Search more.